Trial · NCT03019406
Results by group156
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 156
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | Any TEAEs | 5 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | Any TEAEs | 5 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | Any TEAEs | 5 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3b: Alglucosidase Alfa | Any TEAEs | 5 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | Any Serious TEAEs | 1 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | Any Serious TEAEs | 3 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | Any Serious TEAEs | 0 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3b: Alglucosidase Alfa | Any Serious TEAEs | 2 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | Any AESI | 0 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | Any AESI | 2 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | Any AESI | 1 | Participants | |
| PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) | PAP: Cohort 3b: Alglucosidase Alfa | Any AESI | 1 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | Protocol-defined IARs | 0 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | Protocol-defined IARs | 2 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | Protocol-defined IARs | 1 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 3b: Alglucosidase Alfa | Protocol-defined IARs | 1 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | Algorithm-defined IARs | 0 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | Algorithm-defined IARs | 2 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | Algorithm-defined IARs | 1 | Participants | |
| PAP: Number of Participants With Infusion-associated Reactions (IARs) | PAP: Cohort 3b: Alglucosidase Alfa | Algorithm-defined IARs | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03019406/results